90 micron flaps get the thumbs up

Article

Using a femotsecond laser (IntraLase) to create flaps of 90 microns does not increase the postoperative risk of striae formation or induction of optical aberrations.

Using a femotsecond laser (IntraLase) to create flaps of 90 microns does not increase the postoperative risk of striae formation or induction of optical aberrations, according to Omid Kermani and colleagues from Augenklinik am Neumarkt, Cologne, Germany.

A total of 25 eyes (18 patients) were treated with the femtosecond laser, applying an intended thickness of 90 microns. A further 25 eyes (14 patients) received LASIK flap cuts with a conventional microkeratome (MK 2000; Nidek), applying an intended flap thickness of 130 microns. All eyes were treated for myopia or myopic astigmatism with the Nidek EC CXIII refractive excimer laser.

No vision threatening complications occurred in any of the treatments and in all eyes, the flap could be opened and repositioned after laser ablation. Dr Kermani conceded that the 90 micron flaps were slightly more difficult to lift compared with normal femtosecond flaps of 120 microns.

The mean femtosecond flap thickness was 95 microns with a standard deviation of ±10 microns and the mean microkeratome flap thickness was 115 microns with a standard deviation of ±25 microns.

Ninety percent of all eyes (from both groups) were within ±0.5 D of target refraction and one day after LASIK, all eyes had a visual acuity of 0.8 or more. Furthermore, no eyes lost more than one line of best corrected visual acuity.

Dr Kermani concluded that flaps with a thickness below 100 microns were not associated with an increased postoperative risk.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.